Welcome to our dedicated page for GBT news (Ticker: GBT), a resource for investors and traders seeking the latest updates and insights on GBT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GBT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GBT's position in the market.
Global Blood Therapeutics (GBT) has initiated the Phase 2 portion of a planned Phase 2/3 trial for GBT021601 (GBT601), a next-generation sickle hemoglobin polymerization inhibitor. This trial aims to determine the optimal dose for a subsequent Phase 3 trial. The study seeks to recruit up to 60 adults with sickle cell disease to evaluate safety, tolerability, and efficacy of the drug. Initial data is expected before the end of the year, with the potential to enhance treatment outcomes compared to Oxbryta.
Global Blood Therapeutics (GBT) has partnered with NFL player Tevin Coleman and his family to launch an education campaign for sickle cell disease (SCD) in recognition of World Sickle Cell Day and Father's Day. The initiative, named Sickle Cell Speaks, aims to raise awareness through personal stories and community engagement. Coleman emphasizes the importance of proactive care for SCD, which affects over 100,000 in the U.S. GBT is committed to improving treatment options, including its FDA-approved drug Oxbryta and ongoing clinical trials.
GBT announces positive Phase 1 results for GBT601 supporting advancement to Phase 2/3 trials. New data from a real-world study confirms the effectiveness of Oxbryta (voxelotor) for sickle cell disease (SCD) in patients aged 12 and older. The study shows significant hemoglobin improvements, aligning with prior Phase 3 results. GBT601 demonstrated promise in increasing hemoglobin levels with lower doses compared to Oxbryta. The company plans to commence Phase 2 trials mid-2022 and will share findings at the EHA 2022 Congress.
The GBT Foundation has opened its fourth annual Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program for proposals until July 29, 2022. This initiative aims to improve healthcare access for Sickle Cell Disease (SCD) patients and families through funding up to $100,000 for five U.S.-based nonprofit organizations. The program has previously funded nearly $1 million since 2019, supporting various healthcare improvements for SCD patients. The Foundation emphasizes addressing disparities and challenges intensified by COVID-19.
Global Blood Therapeutics (GBT) has received FDA orphan drug and rare pediatric disease designations for inclacumab and GBT601, both targeting sickle cell disease (SCD). Inclacumab, currently in Phase 3 trials, aims to reduce vaso-occlusive crises (VOCs), a leading cause of hospital readmissions in SCD patients. GBT601, a next-generation HbS polymerization inhibitor, is expected to progress to Phase 2/3 trials by mid-2022. These designations facilitate incentives like market exclusivity and tax credits, supporting GBT's goal of transforming SCD treatment.
Global Blood Therapeutics (GBT) announced on June 1, 2022, that its compensation committee granted restricted stock units totaling 33,700 shares to 10 new employees. This action is part of GBT's Amended and Restated 2017 Inducement Equity Plan, designed to incentivize new hires. The company focuses on developing treatments for underserved communities, particularly for sickle cell disease (SCD), having introduced Oxbryta® (voxelotor) and advancing other pipeline programs.
Global Blood Therapeutics (GBT) announced a conference call and webcast on June 10, 2022, at 3:00 p.m. CEST to discuss recent data on sickle cell programs presented at the EHA Annual Congress. Investors can join the call by dialing (877) 407-3982 or +1 (201) 493-6780. Additionally, GBT will participate in the William Blair conference on June 8 and a Goldman Sachs fireside chat on June 15, both accessible via webcast. GBT is dedicated to developing treatments for sickle cell disease, with innovations like Oxbryta and advanced pipeline programs.
Global Blood Therapeutics (GBT) announced five abstracts related to its sickle cell disease programs to be presented at the 2022 European Hematology Association Congress. Highlights include new real-world evidence on Oxbryta (voxelotor) and findings from the GBT601 Phase 1 study. The RETRO study shows Oxbryta improves hemoglobin levels and reduces hemolytic markers. GBT601 demonstrated good tolerability and improved red blood cell health. Additionally, the SHAPE survey highlights the burden of sickle cell disease and the need for enhanced treatments.
Global Blood Therapeutics (GBT) announced the granting of restricted stock units to 14 new employees totaling 46,400 shares of common stock on May 1, 2022. These awards were made under the company’s Amended and Restated 2017 Inducement Equity Plan as an inducement for employment per NASDAQ Listing Rule 5635(c)(4). Founded in 2011, GBT focuses on treatments for sickle cell disease (SCD), presenting Oxbryta® as the first FDA-approved treatment to inhibit sickle hemoglobin polymerization. The company is advancing its pipeline, including a Phase 3 development program for inclacumab.
FAQ
What is the market cap of GBT (GBT)?
